Invokamet Injury Lawsuits: Legal Options Explained
Discover if you can pursue compensation for serious side effects from Invokamet, the type 2 diabetes drug linked to amputations, ketoacidosis, and more.
Invokamet, a prescription medication for managing type 2 diabetes, combines canagliflozin and metformin to help control blood sugar levels by promoting glucose excretion through urine. Approved by the U.S. Food and Drug Administration (FDA) in 2014, it belongs to the SGLT2 inhibitor class. However, clinical data and patient reports have associated it with severe adverse effects, prompting numerous lawsuits against Janssen Pharmaceuticals and Johnson & Johnson. Patients experiencing complications like lower limb amputations or diabetic ketoacidosis may have grounds for legal action if manufacturers failed to adequately warn about these risks.
Understanding Invokamet and Its Intended Benefits
Type 2 diabetes affects millions, impairing the body’s insulin response and glucose regulation, which can lead to complications such as cardiovascular disease, neuropathy, and reduced life expectancy. Invokamet aims to address this by inhibiting sodium-glucose co-transporter 2 proteins in the kidneys, reducing glucose reabsorption and lowering blood sugar independently of insulin. Marketed as an adjunct to diet and exercise, it offers convenience with its dual-action formula.
Upon FDA approval in August 2014, Janssen promoted Invokamet as a breakthrough for adult type 2 diabetes patients. Initial trials showed efficacy in glycemic control, positioning it alongside related products like Invokana (canagliflozin alone) and Invokamet XR (extended-release version). Despite these benefits, post-marketing surveillance revealed safety concerns that overshadowed its advantages.
Serious Health Risks Linked to Invokamet Use
Independent studies and FDA analyses have identified multiple risks tied to Invokamet and similar SGLT2 inhibitors. These complications can be life-altering or fatal, affecting patients even with normal or slightly elevated blood sugar.
- Lower Limb Amputations: Clinical trials (CANVAS program) found patients on canagliflozin twice as likely to undergo toe, foot, or leg amputations compared to placebo groups after over three years. Risks include full or partial removals, often due to infections or poor circulation.
- Diabetic Ketoacidosis (DKA): This occurs when the body produces excessive blood acids, even in type 2 patients. FDA reported over a dozen cases by 2015, with symptoms like nausea, fatigue, and abdominal pain appearing at lower glucose levels than typical.
- Kidney Damage: Acute kidney injury, chronic kidney disease, and end-stage renal failure have been alleged in lawsuits, linked to dehydration from increased urination or direct nephrotoxicity.
- Bone Fractures: Reduced bone density and higher fracture rates, particularly in the lower extremities, stem from metabolic changes induced by the drug.
- Cardiovascular Events: Heart attacks, strokes, and Fournier’s gangrene (a rare genital infection) have also been reported, exacerbating diabetes-related vulnerabilities.
The Future of AI: Preventing a Big Tech Monopoly >
These risks prompted regulatory actions, highlighting a pattern where benefits did not outweigh harms for some users.
FDA Warnings and Label Changes for Invokamet
The FDA’s response evolved with emerging evidence. In May 2015, it issued a safety communication on DKA risks for SGLT2 inhibitors, noting 20+ cases from 2013-2014 despite atypical presentations in type 2 diabetes.
By May 2017, two CANVAS trials led to a Boxed Warning—the FDA’s strongest alert—for amputation risks specific to canagliflozin products. Labels now mandate warnings about monitoring for foot infections, sores, or pain, and discontinuing use if issues arise. Additional updates addressed ketoacidosis, urging hospitalization for symptoms.
| Risk | FDA Action Date | Key Requirement |
|---|---|---|
| Diabetic Ketoacidosis | May 2015 | Drug Safety Communication; educate on atypical symptoms |
| Leg/Foot Amputations | May 2017 | Boxed Warning added to labels |
| Kidney Injury | Ongoing | Monitor hydration and renal function |
These changes underscore manufacturer obligations to update safety information promptly, forming the basis for failure-to-warn claims.
Legal Basis for Invokamet Injury Claims
Lawsuits against Janssen and Johnson & Johnson typically allege product liability under theories like:
- Failure to Warn: Inadequate disclosure of risks in marketing or labels, depriving doctors and patients of informed choices.
- Design Defect: Inherent flaws in the SGLT2 mechanism causing unavoidable harms.
- Negligent Misrepresentation: Overstating benefits while downplaying dangers pre-approvals.
Many cases seek compensation for medical expenses, lost wages, pain, suffering, and wrongful death. Statutes of limitations vary by state (1-4 years from injury discovery), so timely action is crucial.
Ongoing Litigation: MDL and Key Cases
Federal courts consolidated Invokana/Invokamet suits into Multidistrict Litigation (MDL No. 2756) in the U.S. District Court for the District of New Jersey. This streamlines discovery and pretrial processes for thousands of claims focusing on amputations, DKA, and kidney issues.
Notable filings include Keller Rohrback’s 2017 suit for plaintiff Steven Smith, who endured acute kidney injury and multiple amputations due to alleged warning failures. Similar actions cite CANVAS data showing doubled amputation rates. Settlements have emerged in some MDL tracks, though bellwether trials test case strengths.
As of 2026, litigation continues, with new claims for rarer issues like Fournier’s gangrene. Joining an MDL offers efficiency but requires proving causation via medical records and expert testimony.
Steps to Determine If You Have a Viable Claim
- Review Medical History: Confirm Invokamet use and diagnose a linked injury (e.g., amputation post-treatment).
- Gather Evidence: Collect prescriptions, doctor notes, hospital records, and timelines.
- Consult Specialists: Endocrinologists or pharmacologists can link drug to harm.
- Contact Attorneys: Product liability lawyers offer free evaluations; many work on contingency (no win, no fee).
- File Within Deadlines: Check state laws; federal MDL has specific protocols.
Pharmacovigilance data strengthens claims, as FDA adverse event reports exceed thousands for SGLT2 drugs.
Compensation Types in Successful Invokamet Lawsuits
Awards vary by injury severity:
| Injury Type | Potential Damages |
|---|---|
| Amputation | $1M–$10M+ (medical, rehab, lost income) |
| DKA Hospitalization | $100K–$500K |
| Kidney Failure | $500K–$5M (dialysis, transplant) |
| Bone Fractures | $50K–$300K |
Punitive damages may apply if egregious misconduct is proven. Past settlements in SGLT2 MDLs have reached multimillions per plaintiff.
Alternatives to Invokamet and Risk Mitigation
Patients should discuss alternatives like GLP-1 agonists, DPP-4 inhibitors, or insulin with physicians. Monitoring includes regular foot exams, hydration, ketone tests, and renal panels. Discontinue if symptoms emerge and report to FDA MedWatch.
Frequently Asked Questions (FAQs)
Can I sue if I had an amputation after taking Invokamet?
Yes, if records show use preceded the injury and warnings were insufficient at the time. MDL participation is common.
What is the deadline to file an Invokamet lawsuit?
Varies by state; often 2 years from discovery. Consult a lawyer immediately.
Has Invokamet been recalled?
No full recall, but labels carry Boxed Warnings. Litigation focuses on pre-warning use.
Do I need to prove Invokamet caused my injury?
Yes, via medical experts linking temporal association, exclusion of other causes, and drug mechanisms.
Are settlements available now?
Some tracks have resolved; others await trials. Attorneys track updates.
References
- Invokana, Invokamet and Invokamet XR lawsuits — Drug Injury Lawyers Blog. 2013-ongoing. https://www.druginjurylawyersblog.com/invokana-invokamet-and-invokamet-xr-lawsuits/
- Keller Rohrback Files Suit Against Manufacturers of Type 2 Diabetes Drug Invokana — Keller Rohrback LLP. 2017-11-09. https://www.kellerrohrback.com/news/keller-rohrback-files-suit-manufacturers-type-2-diabetes-drug-invokana
- Invokamet Lawsuit – Diabetic Ketoacidosis Litigation — Olsen Law APC. 2013-ongoing. https://www.olsenlawapc.com/personal-injury/product-liability/sglt2-inhibitors/invokamet/
- Invokana Lawsuit Lawyers — Stark & Stark. 2013-ongoing. https://www.stark-stark.com/service/personal-injury/defective-drugs/invokana-lawsuit/
- Invokana Lawsuit | We Stand Up For You® — CR Legal Team. 2017-ongoing. https://www.crlegalteam.com/invokana-injury-lawyer/
Similar Articles
Read full bio of medha deb
